Simply Wall St
4 min read
The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and economic uncertainty, identifying high-growth tech stocks requires careful consideration of their potential for innovation and resilience amidst broader market fluctuations.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
ADMA Biologics |
20.01% |
24.80% |
★★★★★☆ |
|
Exelixis |
10.68% |
20.92% |
★★★★★☆ |
|
Palantir Technologies |
26.87% |
29.45% |
★★★★★★ |
|
Workday |
11.19% |
32.11% |
★★★★★☆ |
|
Circle Internet Group |
26.50% |
88.24% |
★★★★★☆ |
|
RenovoRx |
65.52% |
68.63% |
★★★★★☆ |
|
Gorilla Technology Group |
32.75% |
122.61% |
★★★★★☆ |
|
OS Therapies |
56.64% |
68.61% |
★★★★★☆ |
|
Zscaler |
15.72% |
40.94% |
★★★★★☆ |
|
Procore Technologies |
11.61% |
114.49% |
★★★★★☆ |
Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.
Let’s review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $758.03 million.
Operations: Gyre focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily through its Gyre Pharmaceuticals segment, which reported $107.27 million. The company is engaged in the anti-inflammatory and anti-fibrotic drug market, reflecting its commitment to addressing organ fibrosis.
Gyre Therapeutics, recently added to the S&P Global BMI Index, showcases robust growth with a 26% annual increase in revenue and an impressive 49.3% surge in earnings. This performance is particularly notable given the broader US market averages of 10.4% and 16%, respectively. Despite challenges such as supply chain disruptions impacting its Etorel rollout, the company’s strategic moves, including successful Phase 3 trials of Pirfenidone for pneumoconiosis treatment in China, underline its innovative edge and potential for sustained growth amidst industry uncertainties.
-
Navigate through the intricacies of Gyre Therapeutics with our comprehensive health report here.
-
Examine Gyre Therapeutics’ past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes novel therapies for diseases with unmet needs, focusing on cardiovascular indications globally, with a market cap of $3.08 billion.
